Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, Furse S, Hengstler JG, Jenkins B, Karnebeek K, Kelly DA, Koot BG, Koulman A, Meierhofer D, Melton PE, Mori TA, Snowden SG, van Mourik I, Vreugdenhil A, Wiegand S, Mann JP; EU‐PNAFLD investigators.
Hudert CA, et al. Among authors: meierhofer d.
Hepatol Commun. 2022 Aug;6(8):1934-1948. doi: 10.1002/hep4.1955. Epub 2022 Apr 11.
Hepatol Commun. 2022.
PMID: 35411667
Free PMC article.